Anthem Biosciences IPO is a book-built issue IPO, aiming to raise ₹27.56 crore. It comprises of a fresh issue of 22.41 lakh equity shares. The bidding window was open from July 9, 2025, to July 11, 2025, with the IPO allotment to be finalised on July 14, 2025. Anthem Biosciences is scheduled to list on BSE SME on July 16, 2025.
The IPO was priced at a range of ₹115-₹123 per share with a lot size of 2000 shares. The public issue received bids for 27,85,17,000 shares against 14,93,000 shares available, resulting in an overall subscription of 186.55 times. NIIs led the response, subscribing 353.14 times their quota, followed by retail investors at 172.06 times.
How to Check Anthem Biosciences IPO Allotment Status Online on NSE?
Go to the application status page.
Select "Equity and SME IPO bids".
Choose "Anthem Biosciences" from the Issue Name dropdown.
Provide your Application Number or PAN.
Click on Submit.
How to Check Anthem Biosciences IPO Allotment Status Online on BSE?
Go to the application status page.
Select "Equity" under the Issue Type.
Choose "Anthem Biosciences" from the Issue Name dropdown.
Provide your Application Number or PAN.
Click on “I am not a robot” and submit.
How to Check Anthem Biosciences IPO Allotment Status Online on the Registrar’s Website?
Go to the registrar’s official website.
Select "Anthem Biosciences" from the company list.
Enter your Client ID, Application Number, or PAN.
Click on Submit.
Anthem Biosciences IPO Details
Anthem Biosciences' ₹27.56 crore IPO, priced at a range of ₹115-₹123 per share, was subscribed 186.55 times overall. The IPO is a fresh issue of 22.41 lakh equity shares. Bidding took place from July 9 to July 11, 2025, with the Anthem Biosciences IPO allotment status on July 14, 2025. Retail investors subscribed 172.06 and NIIs 353.14 times. Listing is expected on July 16, 2025.
Allocation Quota for Anthem Biosciences
The table below breaks down the Anthem Biosciences share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
Investor Category | Shares Offered |
Market Maker Shares Offered | 1,13,000 (5.04%) |
QIB Shares Offered | 10,60,000 (47.30%) |
− Anchor Investor Shares Offered | 6,35,000 (28.34%) |
− QIB (Ex. Anchor) Shares Offered | 4,25,000 (18.96%) |
NII (HNI) Shares Offered | 3,22,000 (14.37%) |
Retail Shares Offered | 7,46,000 (33.29%) |
Total Shares Offered | 22,41,000 (100.00%) |
Data Source: BSE
Anthem Biosciences IPO – Overall Subscription Status
Category | Subscription (times) |
Qualified Institutional Buyers | 85.76 |
Non-Institutional Investors | 353.14 |
Retail Individual Investors | 172.06 |
Total shares | 186.55 |
Note: The subscription details are as of July 11, 2025
Anthem Biosciences Business Overview
Anthem Biosciences Limited was originally incorporated as Anthem Biosciences Private Limited on 16 April 2019 under the Companies Act, 2013. The company was subsequently converted into a public limited entity and renamed Anthem Biosciences Limited on 29 August 2024, following the issuance of a fresh certificate of incorporation by the Registrar of Companies, Mumbai.
The company is engaged in the manufacturing and export of pharmaceutical formulations and nutraceutical products, catering to both domestic and international markets, with a particular focus on African and Asian regions. Its product portfolio includes tablets, capsules, oral liquids, external preparations such as ointments, creams, gels and lotions, as well as oral powders in the form of sachets and dry syrups.
Asston operates a dedicated manufacturing facility in Ambernath, Thane, Maharashtra, and also collaborates with WHO-GMP certified contract manufacturers and FDA-accredited laboratories to ensure compliance with global quality standards. The company oversees the entire supply chain—from production to export—ensuring consistency and reliability in its operations.
The company’s growth strategy is centred on expanding its customer base, diversifying its product offerings, and entering new geographies. It has already registered in Cambodia and is actively pursuing market entry into Laos, Vietnam, Zambia and Nigeria. Anthem Biosciences aims to strengthen its position in the global pharmaceutical landscape by leveraging its manufacturing capabilities, regulatory compliance, and strategic partnerships.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 16, 2025, 7:46 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and asset management, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
